Rifampicin [13292-46-1]
Référence T0681-1ml
Conditionnement : 1mLx10mM(inDMSO)
Marque : TargetMol
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
Rifampicin
(Synonyms: Rimactane, Rifamycin AMP, Rifampin) Copy Product Info
Rifampicin (Rifamycin AMP) is a broad-spectrum antibiotic. Rifampicin has a strong antibacterial effect against Mycobacterium tuberculosis and is also effective against gram-positive and gram-negative bacteria and viruses.
Cas No. 13292-46-1
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.28%
Color:Red
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Rifampicin (Rifamycin AMP) is a broad-spectrum antibiotic. Rifampicin has a strong antibacterial effect against Mycobacterium tuberculosis and is also effective against gram-positive and gram-negative bacteria and viruses. |
| Targets & IC50 | OATP1B1:1.2–1.5 μM, HepG2 cells:145.33 μM, Vero cells:> 10 μg/mL, HeLa cells:270 μg/mL, Huh7 cells:> 20 μM, Osteoblast:130 μg/mL, Hepatocyte cells:> 20 μM, MDCK cells-II:> 20 μM, J774 cells.A1:> 64 μg/mL, THP-1 cells:0.0018 μg/mL, PBMC cells:62.92 μg/mL, MG-63 cells:240 μg/mL, Macrophages:> 100 μM, MRC5 cells:> 100 μM, HEK293 cells:0.3 μM |
| In vitro | METHODS: PC12 cells were treated with Rifampicin (25-100 µM) for 3-24 h. The expression levels of target proteins were detected by Western Blot. RESULTS: At 6 h of incubation, Rifampicin induced a significant increase in GRP78 protein expression in PC12 cells. Prolonged incubation with Rifampicin further enhanced the induction of GRP78 up to 24 h. PC12 cells showed a dose-dependent induction of GRP78 when incubated with Rifampicin at concentrations in the 25-100 µM range. [1] METHODS: Human colon cancer cells LS180 were treated with Rifampicin (10 µM) for 24-144 h. Gene levels were measured by RT-PCR. RESULTS: The total expression of NR1I2 mRNA was reduced by 40% after 24 h of Rifampicin treatment, and the expression of PXR.3 mRNA was reduced by 45% after 24 h of Rifampicin treatment. [2] |
| In vivo | Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentrations [4]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo causes a slight decline in bioluminescence from these catheters compared with the parental signal, but it does not affect bioluminescence in mice infected with mutant H481Y [5]. |
| Synonyms | Rimactane, Rifamycin AMP, Rifampin |
| Molecular Weight | 822.94 |
| Formula | C43H58N4O12 |
| Cas No. | 13292-46-1 |
| Smiles | OC1=C2C3=C4O[C@@](C)(C3=O)O/C=C\[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(/C)\C(=O)NC(C(O)=C2C(O)=C4C)=C1C=NN5CCN(C)CC5 |
| Relative Density. | 1.34 g/cm3 |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 87.5 mg/mL (106.33 mM), Sonication is recommended.  Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.08 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||